Opioid Use Disorder Market Size (2024 –2030)

The Global Opioid Use Disorder Market was valued at USD 3.21 billion and is projected to reach a market size of USD 6.54 billion by the end of 2030. Over the forecast period of 2024-2030, the market is projected to grow at a CAGR of 10.7%.

Opioids are painkillers, but they can cause addiction and major health problems as well. The global challenge of treating opioid addiction is increasing due to the number of people who are battling opioid dependence, government initiatives, and organizational support. However obstacles like trouble getting treatment and problems with behavioral therapies that can cause relapse impede market expansion. The financing and initiatives of the government are essential in promoting treatments for opioid use disorder. Orexo AB is investigating Modia, a digital therapy for individuals with opioid use disorder (OUD), in collaboration with ApexB.io and Magellan Rx Management. Modia offers individualized psychotherapy sessions via mobile apps or PCs. In the meantime, Indivior PLC has successfully acquired Opiant Pharmaceuticals, Inc., expanding its therapeutic offerings for addiction, which now include the experimental opioid overdose therapy candidate OPNT003.

Key Market Insights:

Buprenorphine-based medications account for approximately 55% of the opioid use disorder treatment market share, driven by their effectiveness in managing withdrawal symptoms and reducing cravings with a lower risk of abuse compared to full opioid agonists.

Outpatient treatment programs constitute around 65% of the market demand for opioid use disorder services, reflecting the shift towards community-based care models and the need for long-term management of the condition.

In terms of region, North America holds the largest market share of about 45% for opioid use disorder treatments, attributed to the high prevalence of opioid addiction in the region and significant government initiatives to address the opioid crisis.

The adoption of digital therapeutics and telemedicine solutions for opioid use disorder management is growing at a rate of approximately 20% annually, driven by the need for improved access to treatment, especially in rural areas, and the increasing integration of technology in addiction care.

Global Opioid Use Disorder Market Drivers:

Increasing Acknowledgment of Buprenorphine Patches as an Effective Treatment Strategy to Promote Market Growth.

Patches for treating opioid addiction are becoming more and more popular because they are effective in treating opioid use disorder (OUD). These skin-applied patches have advantages like improved drug delivery and decreased discomfort. They are a useful choice for ongoing opioid therapy, especially for people who require medication continuously. As more patients enter the global market for the treatment of opioid use disorders, such collaborations are anticipated to accelerate the adoption of these therapies in the upcoming years.

Increasing the Number of Addictions to Opioids in Order to Gain Market Share.

Globally, there are serious health issues like cancer and heart disease, which are frequently managed with opioids and other painkillers. But if used for an extended period of time and stopped abruptly, these drugs can cause addiction and withdrawal symptoms. Globally, the prevalence of opioid addiction is increasing; according to the CDC, 2.7 million Americans who are 12 years of age or older will have an opioid use disorder in 2022. Serious consequences like opioid overdose deaths are more likely as a result of these trends.

Opioid Use Disorder Market Challenges and Restraints:

The adverse effects of drugs used in therapy present a barrier to the market for treatments for opioid addiction. These drugs may result in a range of physical symptoms, including cramping in the abdomen, joint pain, nausea, vomiting, diarrhea, constipation, respiratory problems, and muscle soreness. Strong drug reactions can also result in mental health problems like depression. The market is further impacted by alerts issued by regulatory agencies such as the U.S. FDA concerning dental problems associated with specific opioids, like oral buprenorphine dissolution. Even people who have never had dental problems before are susceptible to these conditions, which include cavities, tooth decay, oral infections, and tooth loss. The potential for market growth is constrained by these factors taken together.

Opioid Use Disorder Market Opportunities:

Increased participation from governmental and non-governmental organizations in spreading awareness about the risks of opioid overdose is another factor contributing to the growth of the market for opioid addiction treatment. Numerous organizations have increased their efforts to address and support individuals affected by opioid addiction as the number of cases of addiction is rising sharply. Prevention and treatment of drug abuse have received funding from many nations, including the United States through programs like Health and Human Services (HHS). These initiatives seek to prevent prescription drug abuse and improve access to medication-assisted therapy for treating opioid use disorders. These kinds of programs should encourage more people who are dealing with opioid-related problems to get treatment, which will help the global market in the years to come.

OPIOID USE DISORDER MARKET REPORT COVERAGE:

Global Opioid Use Disorder Market Segmentation: By Drug

• Buprenorphine

• Sublocade

• Belbuca

• Suboxone

• Zubsolv

• Methadone

• Naltrexone

Based on drug class, the market for opioid addiction treatment is divided into three segments: methadone, buprenorphine, and naltrexone. In 2022, buprenorphine is expected to hold a 36% share, leading the market. SUBLOCADE, SUBOXONE, and ZUBSOLV are just a few of the many branded drugs that are widely used in developed nations like the United States and France, contributing to their dominance. Despite an increase in generic options, the methadone market is predicted to grow at a slower rate of 23% as a result of fewer new product launches. The limited range of products that are expected to be available during the forecast period is the main reason why the naltrexone segment has a smaller market share.

Global Opioid Use Disorder Market Segmentation: By Route of Administration

• Intravenous

• Oral

Parenteral (injection-based) and oral routes of administration make up the two main segments of the market for opioid use disorder (OUD) treatment. With a projected market share of 53%, the parenteral segment is anticipated to continue holding the top spot throughout the forecast period. The availability of numerous injectable OUD medications in a range of dosages is what propels this dominance. The preference of many patients for oral medication delivery over injections is expected to cause the oral segment's global market share to grow significantly even though it is predicted to decline.

Global Opioid Use Disorder Market Segmentation: By Age

• 19 to 40

• 41 to 60

• 61 & over

The age groups that make up the market for treatment for opioid use disorders are 19 to 40, 41 to 60, and 61 and older. Due to changing lifestyles and a rise in the use of opioids for pain relief among younger and middle-aged people, the 19 to 40 age group dominated the market in 2022. With a projected market share of 42%, this segment is anticipated to maintain its leadership position in the market throughout the projection period.

Global Opioid Use Disorder Market Segmentation: By Distribution Channel

• Hospital Pharmacies

• Retail Pharmacies & Stores

• Online Pharmacies

Based on distribution channels, the market for drugs for opioid use disorders is divided into hospital pharmacies, retail pharmacies & stores, and online pharmacies. Because patients rely on hospital pharmacies for parenteral medications like buprenorphine, these establishments are predicted to hold a 39% market share. Due to patient preference for filling prescriptions at these locations, retail pharmacies and stores are anticipated to be the second-largest segment. As more people choose the convenience of online platforms to get their medications, internet pharmacies are predicted to grow at the fastest compound annual growth rate (CAGR).

Global Opioid Use Disorder Market Segmentation: By Region

• North America

• Europe

• Asia-Pacific

• South America

• Middle East and Africa

With a predicted share of 45% during the forecast period, North America is anticipated to lead the global market for opioid use disorders. The prevalence of major market players, the large number of Americans impacted by opioid dependence, and the growing number of government initiatives aimed at halting the epidemic are the driving forces behind this leadership. For instance, the National Center for Biotechnology Information (NCBI) stated in 2020 that the number of Americans with opioid use disorder exceeded 2.1 million. Because of the increasing number of patients suffering from opioid dependence and the regular release of new products, Europe's market size is expected to trail that of North America. Due to rising healthcare costs and increased public awareness of the disease, the Asia Pacific region is predicted to grow at the fastest compound annual growth rate (CAGR) during the forecast period. It is also anticipated that markets in other formerly underrepresented regions—South America, the Middle East, and Africa—will grow. The number of patients suffering from opioid dependence will rise, along with healthcare spending and public awareness of opioid use disorder.

COVID-19 Impact on the Global Opioid Use Disorder Market:

The market for opioid use disorder (OUD) has been complicatedly impacted by the COVID-19 pandemic. The pandemic initially caused strain on the world healthcare system, which resulted in the 2020 postponement of elective procedures. As a result, there was less need for opioids to manage pain, which may have decreased the incidence of OUD. But during the pandemic, unforeseen events like postponed doctor's appointments led to a rise in long-term opioid use, which exacerbated cases of OUD. Opioid overdose has emerged as a major cause of injury-related mortality in the United States; the CDC predicts that by 2020, 2.7 million individuals will have experienced an OUD. Due to this combination, the market for OUD treatments was maintained even though there was a slight increase in the number of new opioid users as long as current users continued taking their medications as prescribed.

Latest Trend/Development:

Expanded access initiatives and technological advancements in digital health have been notable trends in the opioid use disorder (OUD) market. Remote addiction management is becoming more popular thanks to digital therapies like Probuphine implants and mobile app-based treatments. Efforts by the government to increase accessibility and affordability, like financing schemes for medication-assisted therapies like buprenorphine, are also becoming more prevalent. These changes are a reflection of the increased focus on cutting-edge therapies and larger support networks to tackle the problems associated with opioid addiction on a global scale.

Key Players:

1. Alkermes

2. Indivior PLC

3. BioDelivery Sciences International

4. Orexo US

5. Titan Pharmaceuticals

6. Omeros Corporation

7. Camurus

8. Hikma Pharmaceuticals PLC

9. AstraZeneca plc

10. Viatris Inc

Market News:

• Titan Pharmaceuticals, Inc. and Indegene joined forces in June 2022 to improve their multichannel digital marketing strategy nationwide and increase the number of people with opioid addiction who can receive Probuphine implants.

• The Buprenorphine Assistance Pilot Program was initiated in April 2023 by the New York State Office of Addiction Services and Supports (OASAS) and the New York State Department of Health (DOH). Through this program, the cost of buprenorphine for treating opioid use disorder (OUD) will be lessened in New York State, improving accessibility to this essential drug.